Key Highlights
● VolitionRx Limited filed its second-quarter 10-Q on August 13, 2026 and hosted an Earnings Call the following morning.
● First-half Revenue was up 112% year over year, a standout growth figure for the blood-test diagnostics company.
● Shares sank 15% on earnings day despite the strong revenue growth, as cash and dilution concerns loomed large.
● VolitionRx, a Singapore-founded, U.S.-listed developer of blood-based Nu.Q diagnostic tests, now faces investor scrutiny over its financing needs.
VolitionRx Limited (NYSE American: VNRX), a Singapore-founded, U.S.-listed developer of blood-based Nu.Q diagnostic tests, filed its second-quarter 10-Q on August 13, 2026, and hosted an earnings call the following morning. The headline figure, first-half revenue up 112% year over year to $1.38 million, drove favorable coverage, but shares closed August 14 at $0.5374, down 14.78% on the day, giving the company a market Capitalization of roughly $4.5 million. The filing also reiterated a "going concern" doubt from auditors, alongside a cash balance of $2.79 million against six-month operating cash burn of $10.4 million. This article verifies the underlying figures against VolitionRx's SEC filings and press releases rather than the percentage headline alone.
Latest Development
VolitionRx's 10-Q, covering the six months ended June 30, 2026, and its accompanying press release confirm second-quarter revenue of $398,657, essentially flat versus the year-earlier quarter, bringing first-half revenue to $1,383,733, up from $653,073 in H1 2025 (a 112% increase, per company disclosure). Quarterly operating expenses fell to $4,554,640, and the operating loss narrowed to $4,155,983, improvements management attributed to cost-cutting. Net loss for the quarter was $7,315,263; for the six months it totaled $14,018,820.
Separately, on August 12, VolitionRx announced prototype data for a rapid, finger-prick lateral-flow test for sepsis-related nucleosome detection, developed under its SUMMIT program, reporting correlation coefficients of 0.85 (Spearman) and 0.881 (Pearson) against its existing lab-based Nu.Q NETs assay. Management also disclosed an ongoing collaboration with Sysmex Corporation on neutrophil extracellular trap (NETs) applications, continued reimbursement-submission work in France for Nu.Q Lung Cancer with Hospices Civils de Lyon, and a pending peer-reviewed publication of a Nu.Q Vet feline lymphoma study that, if published, would trigger a $5 million contractual milestone payment. None of these items involve a signed, revenue-generating licensing agreement as of this writing; management describes discussions with "more than a dozen" diagnostics and liquid-biopsy companies as ongoing.
What the Numbers Show
The 112% growth figure is real but built on a small base: H1 2025 revenue of $653,073 grew to $1.38 million in H1 2026, an increase of about $731,000 in absolute dollars. Nearly all of that growth occurred in Q1 2026 (revenue of $985,076), while Q2 2026 revenue of roughly $399,000 was essentially unchanged from a year earlier, a distinction the 112% headline obscures. The company has not disclosed a separate gross-margin figure in recent filings reviewed.
Cash and equivalents stood at $2.79 million as of June 30, 2026, down from $3.10 million at March 31, 2026, despite the company raising $5.3 million gross during the quarter ($1.2 million via at-the-market Equity sales and $4.1 million via a confidentially marketed public offering), underscoring how quickly proceeds were consumed by operating losses. Six-month cash used in Operating Activities was $10.4 million, or roughly $1.7 million per month on average; management's own disclosure pegs Q2 operating cash burn at $5.2 million, an 18% year-over-year improvement but still well in excess of the current cash balance. Shares outstanding rose from 7.93 million at March 31, 2026, to 13.65 million as of August 11, 2026, a roughly 72% increase in under five months, reflecting continued dilutive issuance. Note that the 1-for-20 reverse split effective April 28, 2026, makes the stock's 52-week range ($0.53–$15.10) and any longer-dated price comparisons unreliable without adjustment.
Why Investors Are Paying Attention
VolitionRx's Nu.Q platform measures circulating nucleosomes in blood, a biomarker approach applicable across oncology, veterinary diagnostics, and now sepsis/inflammation, a broader footprint than many single-indication liquid-biopsy peers. The Sysmex collaboration brings a large, established in-vitro-diagnostics company into the mix, and management's stated goal of monetizing the platform through licensing (upfront payments, royalties, milestones) rather than costly in-house commercialization is a lower-capital-intensity model that could, in theory, extend the company's runway if it lands agreements. The pending $5 million milestone tied to Journal publication and the France reimbursement process for Nu.Q Lung Cancer are concrete, dated catalysts investors are tracking.
Bull Case
Multiple near-term, binary catalysts exist: a peer-reviewed feline lymphoma publication (worth $5 million contractually), potential licensing signings after reportedly advanced talks with over a dozen counterparties, and progress on French reimbursement for Nu.Q Lung Cancer. Operating expenses fell meaningfully year over year, suggesting expense discipline. The sepsis/NETs franchise, addressing a market the company sizes at $3.8 billion, adds a Diversification angle beyond oncology. If even one licensing deal converts to signed terms with upfront cash, it could materially change the balance-sheet picture given the company's tiny current base.
Bear Case
The going-concern opinion was reiterated in the August 2026 10-Q, and the numbers explain why: $2.79 million in cash against roughly $1.7 million in monthly-equivalent operating burn implies a runway measured in weeks to a few months absent new financing. Dilution has been severe and continuous, shares outstanding rose about 72% in under five months even after a 1-for-20 reverse split earlier this year, and a Lind Capital convertible note carried a derivative Liability of $1.17 million at quarter-end. VolitionRx remains out of compliance with NYSE American's equity-listing standard, operating under a remediation plan due by August 2027; failure could risk delisting. Commercial revenue, in absolute dollars, remains near flat quarter over quarter and small relative to the cash burned to generate it. No signed licensing agreement has been verified despite years of "advanced discussions" framing, and the $5 million milestone depends on a peer-review timeline outside the company's control.
What Could Move the Stock Next?
Watch for: publication of the feline lymphoma study (unlocking the $5 million milestone); any announcement of a signed, revenue-bearing licensing agreement; further capital raises, which would likely mean additional dilution; updates on NYSE American compliance standing; a reimbursement decision on Nu.Q Lung Cancer in France; additional sepsis/NETs clinical data; and the Q3 2026 earnings report, which will show whether the cash position stabilized after quarter-end financing activity.
Strong Growth, Bigger Financing Questions
VolitionRx's first-half revenue growth is real in percentage terms but modest in dollars, and it coincides with a going-concern warning, a cash position of under $3 million, continued heavy operating losses, and substantial share dilution, factors that plausibly weighed on sentiment around the August 14 earnings release, though no single announcement was identified as the specific trigger for the day's decline. The company has genuine scientific and Partnership momentum, including the Sysmex collaboration and new sepsis-testing data, plus dated catalysts like the pending feline-lymphoma milestone. But absolute revenue remains small, licensing deals remain unsigned as of this writing, and the Balance Sheet leaves little room for missteps. Investors should weigh the diagnostic-platform potential against the near-term financing and dilution risk clearly documented in the company's own SEC filings.






Please wait processing your request...